High survivin mRNA expression is a predictor of poor prognosis in breast cancer: A comparative study at the mRNA and protein level

Breast Cancer

Volumn 21, Issue 4, 2014, Pages 482-490

  Xu, Chunsen ^a,b   Yamamoto Ibusuki, Mutsuko ^a   Yamamoto, Yutaka ^a   Yamamoto, Satoko ^a   Fujiwara, Saori ^a   Murakami, Keiichi ^a   Okumura, Yasuhiro ^a   Yamaguchi, Lisa ^a   Fujiki, Yoshitaka ^a   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Prognosis; Survivin

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; AROMATASE INHIBITOR; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; NAVELBINE; SURVIVIN; TAXANE DERIVATIVE; TRASTUZUMAB; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

ADOLESCENT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CANCER SPECIFIC SURVIVAL; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISTANT RELAPSE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCORING SYSTEM; TUMOR INVASION; TUMOR VOLUME; VERY ELDERLY; ADULT; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; SECONDARY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904766394     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0403-9     Document Type: Article

References (40)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687-717.
2. Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Hery C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:3620-7.
3. Willett LR. ACP Journal Club. Review: in women 39 to 69 years of age, screening with mammography reduces breast cancer mortality. Ann Intern Med. 2010;152:727-37.
4. Foekens JA, Wang Y, Martens JW, Berns EM, Klijn JG. The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. Drug Discov Today. 2008;13:481-7.
5. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008;14:7988-99.
6. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: 10 years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320-68.
7. Zografos GC, Roukos DH. Innovative biomarker development for personalized medicine in breast cancer care. Biomark Med. 2011;5:73-8.
8. Thiery JP, Sastre-Garau X, Vincent-Salomon B, Sigal-Zafrani X, Pierga JY, Decraene C, et al. Challenges in the stratification of breast tumors for tailored therapies. Bull Cancer. 2006;93:E81-9.
9. Park YH, Kim ST, Cho EY, Choi YL, Ok ON, Baek HJ, et al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤ 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat. 2010;119:653-61.
10. Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer. Surg Oncol. 2011. doi:10.1016/j.suronc.2011.01.001.
11. Altieri DC. New wirings in the survivin networks. Oncogene. 2008;27:6276-84.
12. Guha M, Altieri DC. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle. 2009;8:2708-10.
13. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer. 2011;10:35-46.
14. O'Driscoll L, Linehan R, Kennedy SM, Cronin D, Purcell R, Glynn S, et al. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett. 2003;201:225-36. (Pubitemid 37357172)
15. Kostadima L, Pentheroudakis G, Fountzilas G, Dimopoulos M, Pectasides D, Gogas H, et al. Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat. 2006;100:161-7. (Pubitemid 44631917)
16. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, et al. Prognostic importance of survivin in breast cancer. Br J Cancer. 2003;88:1077-83. (Pubitemid 36560779)
17. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem. 2004;50:1986-93. (Pubitemid 39425834)
18. Yakirevich E, Samkari A, Holloway MP, Lu S, Singh K, Yu J, et al. Total survivin and acetylated survivin correlate with distinct molecular subtypes of breast cancer. Hum Pathol. 2011. doi: 10.1016/j.humpath.2011.07.014.
19. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569-83. (Pubitemid 41511089)
20. Cinieri S, Orlando L, Fedele P, Cusmai A, D'Amico M, Rizzo P, et al. Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference. Ann Oncol. 2007;18 (Suppl 6):vi63-5.
21. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133-44. (Pubitemid 47244357)
22. Ibusuki M, Fu P, Yamamoto S, Fujiwara S, Yamamoto Y, Honda Y, et al. Establishment of a standardized gene-expression analysis system using formalin-fixed, paraffin-embedded, breast cancer specimens. Breast Cancer. 2011. doi:10.1007/s12282-011-0318-x.
23. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, et al. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008;110:465-75. (Pubitemid 351962589)
24. Okumura Y, Yamamoto Y, Zhang Z, Toyama T, Kawasoe T, Ibusuki M, et al. Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. BMC Cancer. 2008;8:287-95.
25. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9:136-222.
26. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006;94:253-58. (Pubitemid 43151544)
27. Lv YG, Yu F, Yao Q, Chen JH, Wang L. The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis. 2010;2:100-10.
28. Nassar A, Lawson D, Cotsonis G, Cohen C. Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol. 2008;16:113-20.
29. Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, et al. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer. 2010;10:639-51.
30. Chu JS, Shew JY, Huang CS. Immunohistochemical analysis of survivin expression in primary breast cancers. J Formos Med Assoc. 2004;103:925-31.
31. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40:83-92.
32. Shebl FM, Pinto LA, Garcia-Pineres A, Lempicki R, Williams M, Harro C, et al. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev. 2010;19:978-81.
33. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010;28:2174-80.
34. Chen G. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1:304-13.
35. Boidot R, Vegran F, Jacob D, Chevrier S, Gangneux N, Taboureau J, et al. The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosom Cancer. 2008;47:299-308. (Pubitemid 351323759)
36. De Schepper S, Bruwiere H, Verhulst T, Steller U, Andries L, Wouters W, et al. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J Pharmacol Exp Ther. 2003;304:881-8. (Pubitemid 36152369)
37. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000;113:4363-71. (Pubitemid 32000697)
38. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A. 2003;100:13791-6. (Pubitemid 37499145)
39. Wang H, Holloway MP, Ma L, Cooper ZA, Riolo M, Samkari A, et al. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem. 2010;285:36129-37.
40. Boidot R, Vegran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med. 2009;23:285-91.